Investment
Features
FeesSafety
Academy
More
Pluang+

Compare T-Rex 2X Long MSTR Daily Target ETF (MSTU) vs Novartis AG (NVS) Price & Performance

T-Rex 2X Long MSTR Daily Target ETFTrade
Novartis AGTrade

Price performance (Past 24H)

Key statistics

T-Rex 2X Long MSTR Daily Target ETF vs Novartis AG — how do they compare? T-Rex 2X Long MSTR Daily Target ETF trades at $30.99, while Novartis AG trades at $139.66 (market cap $262.64B). The key difference: Novartis AG pays a 3.44% dividend while T-Rex 2X Long MSTR Daily Target ETF pays none, and Novartis AG is trading nearer its 52-week high, T-Rex 2X Long MSTR Daily Target ETF nearer its low. Which is the better fit depends on your goals.

MSTUNVS
Sector
Leveraged / InverseHealth
52-Week High
$573.00$168.62
52-Week Low
$14.60$121.80
Market Cap
$262.64B
Enterprise Value
$303.97B
Dividend Yield
3.44%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

T-Rex 2X Long MSTR Daily Target ETF

MSTU, a US stock, trades at $33.31, down 8.64% in the last 24 hours. Technical indicators show a bullish trend with strong moving averages, while oscillators are neutral. The company recently executed a 10:1 reverse stock split and declared a $0.29 dividend for H2-2026. Key support and resistance levels are at $30 and $36, respectively.

The outlook for MSTU is mixed; bullish technicals contrast with negative media sentiment highlighting significant past value erosion. Risks include high volatility and leveraged ETF decay. Investors should weigh technical strength against fundamental uncertainties and sentiment concerns before considering a position.

Novartis AG

Novartis (NVS) is trading at $137.70, down 13.93% following significant clinical trial setbacks for del-desiran and pelacarsen. The stock shows bearish technical signals with support at $133-$136 and resistance at $140-$143. Fundamentally, the company maintains strong profitability with 74.74% gross margins and 22.5% net income margins, though recent pipeline failures have overshadowed solid financial performance.

While Novartis maintains strong financial fundamentals and reiterated 2025-2030 growth guidance, the recent clinical trial failures create near-term uncertainty. The stock faces pressure from pipeline setbacks but offers value at current levels for long-term investors willing to weather development risks. Analyst consensus remains cautious with 68% hold ratings.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About T-Rex 2X Long MSTR Daily Target ETF

MSTU is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the MicroStrategy Incorporated (MSTR) stock. It is designed as a tactical tool for experienced traders to take a bullish (long) position in MSTR, a company known for its significant Bitcoin holdings. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.

Read more on MSTU

About Novartis AG

Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.

Read more on NVS